Dr. Jaclyn Bosco Global Head of Epidemiology & Database Studies in Real World Solutions at IQVIA, is responsible for driving real-world evidence (RWE) generation for regulators, clinicians, patients and payers using passive and primary data collection through clinicians and person-generated health to support the safety and effectiveness of drugs, biologics, and medical devices from early clinical development through the post-approval phase. She identifies the best approach for capturing data on a global scale as well applies local approaches to address market-specific needs. As a thought leader in real world research, she is invited to speak at international congresses and sits on scientific advisory boards and committees.

Alicia Gilsenan, PhD, is Vice President, Epidemiology within RTI-HS and a licensed pharmacist. Dr. Gilsenan’s primary area of expertise is pharmacoepidemiology and therapeutic risk management and the structured benefit-risk assessment of medications. Since joining RTI in 1997, she has applied state-of-the-art approaches to the design, conduct, and analysis of both retrospective and prospective epidemiologic studies, most recently focusing on consultation, design, and implementation of postauthorization safety studies in the US and in Europe in area of vaccine and drug safety. She is adjunct professor in Epidemiology at the UNC-Chapel Hill and teaches an intro to Pharmacovigilance course to graduate students biannually.

Charles is currently Executive Regulatory Science Director at Astrazeneca. He oversees Global Regulatory science and strategy for therapeutic products in the renal, cardiovascular, diabetes, and NASH disease areas. Prior to this role, Charles was a Product Development Team Leader over a 10 year period at Astrazeneca and Roche where he led cross-functional project teams for programs in the early development phase (Ph0 to Ph2b). Previous to that, Charles spent 10 years in Global Regulatory affairs where he held leadership roles on programs across several therapeutic areas in different stages of development. Charles holds BS in Biology from The Johns Hopkins University, MS from University of Virginia, MBA from Columbia Business School

Sarah currently serves as senior director of global regulatory policy for oncology at Lilly. She previously served as senior director of science and regulatory advocacy for the Pharmaceutical Research and Manufacturers of America (PhRMA) where she led their regulatory advocacy efforts on key issues including real-world evidence, clinical development, human drug review program, and CGTs. Sarah also worked for the American Association for Cancer Research (AACR) where she led their efforts to modernize the regulatory process and engage in the development and implementation of programmatic and policy initiatives with the US FDA Oncology Center of Excellence.

Keri Monda, PhD, is an Executive Director of Observational Research and Head of the Data & Analytics Center within the Center for Observational Research (CfOR) at Amgen. In her role, she leads a team of epidemiologists and data scientists responsible for generating real-world evidence in support of programs from research and early development through launch and end of patent expiry, and oversees a large, integrated real-world data and analytics ecosystem. Prior to her time at Amgen, Keri was a genetic epidemiologists on faculty in the Department of Epidemiology at the University of North Carolina, Chapel Hill.

Motiur Rahman is a Senior Epidemiologist at Real-World Evidence (RWE) Analytics in the Office of Medical Policy, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA). His responsibilities include developing guidance, improving internal Agency processes, stakeholder engagement, collaborating on Agency-funded demonstration projects, and providing consultancy on RWE study submissions. He joined FDA in 2022 after a 10+ years of working experience in academia and industry in conducting observational studies across a wide range of therapeutic areas. Dr. Rahman is a Pharmacist by training and holds a PhD in Pharmacoepidemiology and Master’s in Statistics.

Camille Jackson is the Director and Head of Regulatory Policy at Flatiron Health, bringing nearly 20 years of experience within policy and program management across various corners of the life sciences sector. Earlier in her career, Camille held roles at Clarivate, Sanofi, PhRMA, The World Bank, NIH, The George Washington University, and the American Academy of Child and Adolescent Psychiatry.

Lina Titievsky, MPH PhD, is a head of Hepatology and Classic and Established Products Epidemiology in Global Epidemiology at GSK. Prior to joining GSK, Lina has worked across multiple therapeutic areas including drugs, vaccines, and cell & gene therapies. Prior to joining GSK, Lina's professional journey included her work as an epidemiologist at Pfizer, Intercept and Vertex. In her current role, she leads a group of epidemiologists responsible for generating evidence ranging from support of discovery and pre-clinical through regulatory approval. Lina holds a PhD in Epidemiology from Columbia University.

Adrian Cassidy is the Vice President and Head of Global Evidence Generation at Novartis with responsibility to develop novel data and evidence applications across the development lifecycle of innovative medicines. As an epidemiologist, Adrian has over 20 years of industry and public sector experience in real world evidence generation, as well as an established track record of building and leading highly successful evidence generation groups and data/digital/analytics platforms. Adrian is passionate about solving healthcare challenges and transforming clinical practice to deliver outcomes that matter for patients.